Aug 11,2016

Ascensia Diabetes' new FDA-cleared glucometer wirelessly connects to Medtronic's new insulin pump

Ascensia Diabetes Care, a new business unit created this year when Panasonic Healthcare Holdings acquired Bayer Diabetes Care, has announced the launch and FDA 510(k) clearance of its Contour Next Link blood glucose monitor. Ascensia makes a line of connected and non-connected fingerstick glucometers. The Contour Next Link is a version that sends data wirelessly to Medtronic's MiniMed 630G insulin pump. According to Ascensia, it's the only FDA-cleared glucometer that connects to that pump, a new Medtronic offering that also just launched today .

REGULATORY FDA

#bgm

View Analyst & Ambassador Comments
Go to original news
Aug 17,2016

Anthem Blue Cross adds Spanish-language telemedicine, diabetes prevention tools

Also this week, Anthem Blue Cross made a diabetes prevention program available to community groups such as Black Women for Wellness and Valley Jewish Community Center, via a partnership with Solera Health, which offers healthy lifestyle coaching and weekly classes to help prevent and manage diabetes. The yearlong program will integrate Solera’s network of community groups as well as national and digital DPP programs, including offerings from HealthSlate, Retrofit, Blue Mesa Health and Lark..

COLLABORATION PARTNERSHIP

#insurance

#coaching

View Analyst & Ambassador Comments
Go to original news
Aug 30,2016

UK-backed study tests wearable, motivational app for diabetes prevention

King's Health Partners, an academic science center, and health wearable company Buddi, both UK-based, are testing a combination of a wearable device and a mobile app to help keep at-risk patients from developing Type 2 diabetes. The randomized control trial, which starts next month, will follow 200 patients with prediabetes over the course of a year in the London boroughs of Lambeth and Southwark. The study is funded in part by the UK government, via a grant from InnovationUK. Buddi has manufactured a wearable mPERS product for a number of years, but this is among the first tests of a prediabetes product called Nujjer.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Aug 31,2016

Study finds Canary Health’s digital diabetes management program helpful across five key health indicators

Researchers at Stanford Medical School just completed a study on the efficacy of Canary Health’s online, digital diabetes program that allows people living with diabetes to self-manage their health through online workshops, coaching, and medication adherence and emotional support. Working from a population of over 1,000 and spanning six months, the study found positive outcomes across five key health indicators– blood sugar levels, medication adherence and exercise all improved, hypoglycemic symptoms decreased in frequency, and depression symptoms improved.

CLINICAL STUDY

#coaching

View Analyst & Ambassador Comments
Go to original news
Aug 01,2016

Insulet Corporation to Present at Upcoming Investor Conferences

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management will present at three upcoming investor conferences in New York City, New York: The 2016 Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 9:10am (Eastern Time), The Baird 2016 Global Healthcare Conference on Wednesday, September 7, 2016 at 11:25am (Eastern Time), and The Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016 at 2:15pm (Eastern Time).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Aug 03,2016

Insulet Reports Second Quarter 2016 Financial Results

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced financial results for the three months ended June 30, 2016. Second quarter 2016 revenue increased 44% to $87.3 million, compared to $60.6 million in the second quarter of 2015.

View Analyst & Ambassador Comments
Go to original news
Aug 04,2016

Tandem Diabetes Care to Present at the 2016 Wedbush PacGrow Healthcare Conference

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim®, t:slim G4™ and t:flex® Insulin Pumps, today announced that Kim Blickenstaff, president and CEO, will present a company update at the 2016 Wedbush PacGrow Healthcare Conference in New York, NY. The presentation will take place on Tuesday, August 16, 2016 at 1:55 PM Eastern Time (10:55 AM Pacific Time).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Aug 04,2016

Nemaura Medical Inc., completes second FDA Pre-submission meeting and appoints Navigant to submit IDE for Nemaura’s sugarBEAT® system

Nemaura Medical Inc., a medical device company developing a minimally invasive, needle-free, wireless CGM (Continuous Glucose Monitoring) patch known as sugarBEAT®, today announced that it recently held a second pre-submission meeting with the FDA to discuss the clinical program for its sugarBEAT® system, for the purpose of a PMA submission in the USA. Nemaura Medical anticipates completing the clinical program and submitting the PMA application around mid 2017.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 04,2016

BD Announces Results for 2016 Third Fiscal Quarter

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced quarterly revenues of $3.198 billion, as reported, for the third fiscal quarter ended June 30, 2016, an increase of 2.5 percent over the prior-year period revenues as reported.

View Analyst & Ambassador Comments
Go to original news
Aug 09,2016

Senseonics Reports Topline Accuracy Results from U.S. Pivotal Study of Eversense CGM System.

enseonics Holdings, Inc. (NYSE-MKT:SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced topline results of the PRECISE II (A Prospective, Multicenter Evaluation of the Accuracy of a Novel Continuous Implanted Glucose Sensor) Clinical Investigation. Results from the 90 adults with diabetes generated over 16,000 comparative glucose data points and demonstrated strong accuracy for the 90-day continuous wear period with a mean absolute relative difference (MARD) of 8.8% across the 40-400 mg/dL range when compared to YSI blood reference values.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES